Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Enterprise Value (2016 - 2025)

Cytokinetics (CYTK) has disclosed Enterprise Value for 16 consecutive years, with -$882.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value changed N/A to -$882.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$882.2 million, a N/A change, with the full-year FY2025 number at -$882.2 million, changed N/A from a year prior.
  • Enterprise Value was -$882.2 million for Q4 2025 at Cytokinetics, down from -$737.1 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$350.3 million in Q2 2021 to a low of -$1.1 billion in Q2 2024.
  • A 5-year average of -$679.7 million and a median of -$619.3 million in 2024 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: plummeted 92.83% in 2021, then skyrocketed 37.81% in 2023.
  • Cytokinetics' Enterprise Value stood at -$471.6 million in 2021, then tumbled by 66.27% to -$784.2 million in 2022, then grew by 21.55% to -$615.2 million in 2023, then tumbled by 64.51% to -$1.0 billion in 2024, then grew by 12.83% to -$882.2 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Enterprise Value are -$882.2 million (Q4 2025), -$737.1 million (Q3 2025), and -$783.2 million (Q2 2025).